Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab (Rituxan).

Literature DB >> 20448016

Rituximab (Rituxan).

David T Selewski¹, G V Shah, R J Mody, P A Rajdev, S K Mukherji.

Abstract

Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.

Entities: Chemical

Mesh：

Substances：

Year: 2010 PMID： 20448016 PMCID： PMC7965451 DOI： 10.3174/ajnr.A2142

Source DB: PubMed Journal: AJNR Am J Neuroradiol ISSN： 0195-6108 Impact factor: 3.825

14 in total

1. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab.

Authors: Stuart L Goldberg; Andrew L Pecora; Robert S Alter; Mark S Kroll; Scott D Rowley; Stanley E Waintraub; Kavita Imrit; Robert A Preti
Journal: Blood Date: 2002-02-15 Impact factor: 22.113

2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245

Review 3. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.

Authors: M D Pescovitz
Journal: Am J Transplant Date: 2006-05 Impact factor: 8.086

4. Persistent antibody depletion after rituximab in three children with autoimmune cytopenias.

Authors: Mehdi Mohammad G Adeli; Brian H Eichner; Courtney Thornburg; Larry Williams
Journal: Pediatr Hematol Oncol Date: 2009-11 Impact factor: 1.969

5. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Authors: P McLaughlin; A J Grillo-López; B K Link; R Levy; M S Czuczman; M E Williams; M R Heyman; I Bence-Bruckler; C A White; F Cabanillas; V Jain; A D Ho; J Lister; K Wey; D Shen; B K Dallaire
Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544

6. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors: Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal: N Engl J Med Date: 2004-06-17 Impact factor: 91.245

7. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors: M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal: Blood Date: 1994-01-15 Impact factor: 22.113

Review 8. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors: Kenneth R Carson; Daniele Focosi; Eugene O Major; Mario Petrini; Elizabeth A Richey; Dennis P West; Charles L Bennett
Journal: Lancet Oncol Date: 2009-08 Impact factor: 41.316

9. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection.

Authors: Edward Shelton; Michelle Yong; Solomon Cohney
Journal: Nephrology (Carlton) Date: 2009-10 Impact factor: 2.506

10. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors: D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal: Blood Date: 1994-10-15 Impact factor: 22.113

6 in total

Review 1. Rituximab and minimal change nephrotic syndrome: a therapeutic option.

Authors: Takashi Takei; Kosaku Nitta
Journal: Clin Exp Nephrol Date: 2011-05-26 Impact factor: 2.801

Review 2. Rituximab for treating inhibitors in people with inherited severe hemophilia.

Authors: Lucan Jiang; Yi Liu; Lingli Zhang; Cristina Santoro; Armando Rodriguez
Journal: Cochrane Database Syst Rev Date: 2017-07-07

3. Rituximab for treating inhibitors in people with inherited severe hemophilia.

Authors: Lucan Jiang; Yi Liu; Lingli Zhang; Cristina Santoro; Armando Rodriguez
Journal: Cochrane Database Syst Rev Date: 2020-08-03

4. Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?

Authors: Lakshmi Kannan
Journal: Cureus Date: 2022-02-17

5. Protective effects of rituximab on puromycin-induced apoptosis, loss of adhesion and cytoskeletal alterations in human podocytes.

Authors: Stefanie Jeruschke; Dana Alex; Peter Friedrich Hoyer; Stefanie Weber
Journal: Sci Rep Date: 2022-07-19 Impact factor: 4.996

6. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.

Authors: Okjae Lim; Yuna Lee; Hyejin Chung; Jung Hyun Her; Sang Mi Kang; Mi-young Jung; Bokyung Min; Hyejin Shin; Tae Min Kim; Dae Seog Heo; Yu Kyeong Hwang; Eui-Cheol Shin
Journal: PLoS One Date: 2013-01-11 Impact factor: 3.240

6 in total